Revenue
2010
2011
2012
2013
2014
2015
2016
2021
2022
2023
2024
2025
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC)
Price$1.62Cached quote
Net income
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.1M | $3.5M | $2.0M | $171,169 | $178,146 | — | — | — | — | $0 | $0 | $773 | $1,249 | $921 | $5,398 | $1,167 |
| Gross profit | $5.1M | $1.1M | $456,517 | −$70,794 | −$97,749 | — | — | — | — | — | — | — | $1,249 | $921 | $3,260 | $1,167 |
| Gross margin | 56.51% | 31.27% | 23.38% | −41.36% | −54.87% | — | — | — | — | — | — | — | 100.00% | 100.00% | 60.39% | 100.00% |
| Research & development | $5.0M | $5.1M | $6.9M | $4.9M | $3.9M | $2.1M | $1.5M | $715,086 | $735,333 | — | — | — | — | — | — | — |
| Operating expenses | $12.4M | $13.0M | $13.9M | $11.9M | $10.2M | $6.8M | $5.8M | $3.4M | $3.1M | $32,611 | $30,915 | $36,687 | $26,342 | $14,654 | $30,688 | $7,211 |
| Operating income | −$4.2M | −$11.9M | −$12.0M | −$10.0M | −$10.2M | −$4.9M | −$5.8M | −$3.4M | −$3.1M | −$32,611 | −$30,915 | −$35,914 | −$25,093 | −$13,733 | — | — |
| Operating margin | −46.46% | −344.26% | −612.32% | −5,860.15% | −5,735.86% | — | — | — | — | — | — | −4,646.05% | −2,009.05% | −1,491.10% | — | — |
| EBITDA | −$4.0M | −$11.6M | −$11.8M | −$9.9M | −$10.1M | −$4.9M | −$5.8M | — | — | — | — | — | — | — | — | — |
| EBITDA margin | −43.58% | −337.11% | −602.12% | −5,790.85% | −5,690.54% | — | — | — | — | — | — | — | — | — | — | — |
| Net income | −$3.6M | −$12.3M | −$11.9M | −$10.0M | −$9.9M | −$13.6M | −$6.8M | −$5.1M | −$5.1M | −$47,775 | −$62,863 | −$36,244 | −$30,554 | −$13,960 | −$27,604 | −$6,044 |
| Net profit margin | −39.63% | −356.74% | −607.42% | −5,841.95% | −5,584.28% | — | — | — | — | — | — | −4,688.75% | −2,446.28% | −1,515.74% | −511.37% | −517.91% |
| Basic EPSper basic share | -$0.54 | -$2.76 | -$3.90 | -$3.78 | -$5.58 | -$15.12 | -$10.26 | -$10.98 | -$13.86 | -$0.18 | -$0.18 | -$0.18 | -$0.18 | $0.00 | -$0.18 | — |
| Diluted EPSper diluted share | -$0.54 | -$2.76 | -$3.90 | -$3.78 | -$5.58 | -$15.12 | -$10.26 | -$10.98 | -$13.86 | -$0.18 | -$0.18 | -$0.18 | -$0.18 | $0.00 | -$0.18 | — |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
Rosa David A | 1.08M |
Wambeke David J. | 1M |
McClurg Ronald W. | 444.12K |
Christianson Mark | 198.67K |
BUCKMAN PAUL | 178.73K |
MATHIESEN JEFFREY S | 156.34K |
Mertens Steve | 152.14K |
Andrle Edward | 133.93K |
Mills Jason Richard | 49.69K |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Mar 30, 2026Form 4 | Christianson MarkBusiness Development Director | SellCommon Stock | 15.4K | $0.74 | $11.4K | 198.9K |
| Mar 13, 2026Form 4 | Christianson MarkBusiness Development Director | SellCommon Stock | 100 | $0.80 | $80.00 | 214.3K |
| Mar 12, 2026Form 4 | Christianson MarkBusiness Development Director | SellCommon Stock | 817 | $0.80 | $653.60 | 214.4K |
| Mar 11, 2026Form 4 | Christianson MarkBusiness Development Director | SellCommon Stock | 2.1K | $0.80 | $1.7K | 215.2K |
| Mar 10, 2026Form 4 | Christianson MarkBusiness Development Director | SellCommon Stock | 11.6K | $0.80 | $9.3K | 217.3K |